TheraCryf
plc
("TheraCryf", the "Company" or the "Group")
TheraCryf Research and Development Day -
13 June 2024
Alderley Park, 13 June 2024
- TheraCryf plc (AIM: TCF), formerly Evgen Pharma
plc, the clinical stage drug development company focussing on
oncology and neuropsychiatry, announces that it is
holding a Research and Development update event today at
09:30am.
The management team and external speakers will
be providing an update on TheraCryf, including the Chronos
acquisition and update on the integration; discussion about the
clinical programme in glioblastoma and the preclinical programmes
in neuropsychiatry. The session will also include a discussion
about market potential and the ongoing strategy.
Speakers will include members of the TheraCryf
(and former Chronos) management and scientific team, and external
speakers including Dr Marjolein Geurts, neuro-oncologist and Dr
Wouter Vanbilloen MD, neurology resident from Erasmus University
Medical Center.
Please note that the Erasmus team will provide a
new update from their research on the combination of SFX-01 and
radiation in certain glioblastoma cells derived from patients. They
have observed a positive combination effect of SFX-01 and radiation
which has also been observed with SFX-01 in laboratory models of
glioblastoma in other centres.
The event will be held at the offices of
Instinctif Partners located at
65 Gresham Street, London EC2V 7NQ and is open to sell-side
analysts and all existing and potential shareholders. Investors and
analysts will be able attend the event in person (please register
at TheraCryf@instinctif.com) or virtually via the Investor Meet
Company platform
HERE.
-
Ends-
Enquiries
|
TheraCryf plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44 (0)1625 315
090
enquiries@theracryf.com
|
|
Cavendish Capital Markets (NOMAD and
Broker)
Geoff Nash / Teddy
Whiley / Rory Sale (Corporate Finance)
Nigel Birks / Harriet Ward
(ECM)
|
+44 20 7220
0500
|
|
Instinctif Partners
Melanie Toyne-Sewell / Jack
Kincade
|
+44 207 457 2020
theracryf@Instinctif.com
|
About TheraCryf plc
TheraCryf is the clinical stage drug
development company focussing on oncology and neuropsychiatry. The
Company has a broad clinical and preclinical pipeline in
indications such as neurodevelopmental disorders, glioblastoma*,
addiction, anxiety and narcolepsy* [*orphan indications]. Its
strategy is to generate compelling data sets to proof of concept
and/or later phase II to partner its clinical programmes with
mid-size to large pharma. As well as a number of industry
partnerships with companies, including Stalicla, in
neurodevelopment disorders and has sourced programmes from
companies such as Takeda and Shire, the Company has worked with and
has ongoing collaborations with major universities, hospitals and
government organisations such as the University of Manchester,
Sapienza (Università di Roma), Kings College London and University
of Connecticut.
The Company has its headquarters and
registered office at Alderley Park, Cheshire. It is listed on AIM
in London and trades under the ticker symbol TCF.
For further information, please
visit: www.theracryf.com